JPWO2021069705A5 - - Google Patents

Download PDF

Info

Publication number
JPWO2021069705A5
JPWO2021069705A5 JP2022521718A JP2022521718A JPWO2021069705A5 JP WO2021069705 A5 JPWO2021069705 A5 JP WO2021069705A5 JP 2022521718 A JP2022521718 A JP 2022521718A JP 2022521718 A JP2022521718 A JP 2022521718A JP WO2021069705 A5 JPWO2021069705 A5 JP WO2021069705A5
Authority
JP
Japan
Prior art keywords
alkyl
branched
membered
pharmaceutically acceptable
linear
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Granted
Application number
JP2022521718A
Other languages
English (en)
Japanese (ja)
Other versions
JP2022551185A (ja
JP7724394B2 (ja
Publication date
Application filed filed Critical
Priority claimed from PCT/EP2020/078483 external-priority patent/WO2021069705A1/en
Publication of JP2022551185A publication Critical patent/JP2022551185A/ja
Publication of JPWO2021069705A5 publication Critical patent/JPWO2021069705A5/ja
Application granted granted Critical
Publication of JP7724394B2 publication Critical patent/JP7724394B2/ja
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

JP2022521718A 2019-10-09 2020-10-09 イソインドリノン化合物 Active JP7724394B2 (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
CH01281/19 2019-10-09
CH12812019 2019-10-09
PCT/EP2020/078483 WO2021069705A1 (en) 2019-10-09 2020-10-09 Isoindolinone compounds

Publications (3)

Publication Number Publication Date
JP2022551185A JP2022551185A (ja) 2022-12-07
JPWO2021069705A5 true JPWO2021069705A5 (enExample) 2023-10-17
JP7724394B2 JP7724394B2 (ja) 2025-08-18

Family

ID=68242216

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2022521718A Active JP7724394B2 (ja) 2019-10-09 2020-10-09 イソインドリノン化合物

Country Status (4)

Country Link
US (1) US20220242846A1 (enExample)
EP (1) EP4041231A1 (enExample)
JP (1) JP7724394B2 (enExample)
WO (1) WO2021069705A1 (enExample)

Families Citing this family (28)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP4076464A4 (en) * 2019-12-17 2024-06-12 Orionis Biosciences, Inc. Compounds modulating protein recruitment and/or degradation
US20240050428A1 (en) * 2020-10-07 2024-02-15 Cullgen (Shanghai), Inc. Compounds and methods of treating cancers
US20240085421A1 (en) 2021-01-13 2024-03-14 Monte Rosa Therapeutics, Inc. Methods for the identification of degrons
US20240261274A1 (en) 2021-01-13 2024-08-08 Monte Rosa Therapeutics, Inc. Treatment of myc-driven cancers with gspt1 degraders
JP2024504932A (ja) 2021-01-13 2024-02-02 モンテ ローザ セラピューティクス， インコーポレイテッド イソインドリノン化合物
CN117242060A (zh) * 2021-01-13 2023-12-15 蒙特罗萨医疗公司 异吲哚啉酮化合物
WO2022200857A1 (en) * 2021-03-22 2022-09-29 Monte Rosa Therapeutics Ag Pharmaceutical compositions for use in the prevention and treatment of a disease or disorder caused by or associated with one or more premature termination codons
EP4347860A1 (en) 2021-06-04 2024-04-10 Monte Rosa Therapeutics, Inc. E3 ligase fusion proteins for proximity detection
CN115504963A (zh) * 2021-06-22 2022-12-23 苏州开拓药业股份有限公司 一种c-Myc蛋白降解剂
JP2024527628A (ja) * 2021-07-19 2024-07-25 メッドシャイン ディスカバリー インコーポレイテッド ヘテロアリール－３－ピペリジンジオン化合物その使用
WO2023069720A1 (en) * 2021-10-22 2023-04-27 Monte Rosa Therapeutics, Inc. Compounds that mediate protein degradation and methods of use thereof
WO2023069731A1 (en) * 2021-10-22 2023-04-27 Monte Rosa Therapeutics, Inc. Compounds that mediate protein degradation and methods of use thereof
WO2023069708A1 (en) * 2021-10-22 2023-04-27 Monte Rosa Therapeutics, Inc. Compounds that mediate protein degradation and uses thereof
WO2023069700A1 (en) * 2021-10-22 2023-04-27 Monte Rosa Therapeutics, Inc. Compounds that mediate protein degradation and methods of use thereof
WO2023091567A1 (en) 2021-11-17 2023-05-25 Monte Rosa Therapeutics, Inc. Degron and neosubstrate identification
US12187699B2 (en) 2022-04-14 2025-01-07 Bristol-Myers Squibb Company GSPT1 compounds and methods of use of the novel compounds
WO2024015855A1 (en) 2022-07-13 2024-01-18 Monte Rosa Therapeutics, Inc. COMBINATION THERAPY COMPRISING GSPT1-DIRECTED MOLECULAR GLUE DEGRADERS AND PI3K/AKT/mTOR PATHWAY INHIBITORS
WO2024015565A1 (en) * 2022-07-14 2024-01-18 Monte Rosa Therapeutics, Inc. Methods of preparing an isoindolinone derivative and crystal forms thereof
WO2024027795A1 (zh) * 2022-08-04 2024-02-08 苏州开拓药业股份有限公司 包含Myc蛋白降解剂类生物活性化合物的抗体药物偶联物及其制备方法和用途
CN115636811A (zh) * 2022-08-17 2023-01-24 成都分迪药业有限公司 异吲哚啉苄胺衍生物的合成方法
EP4584259A1 (en) 2022-09-09 2025-07-16 Innovo Therapeutics, Inc. Ck1alpha and dual ck1alpha / gspt1 degrading compounds
WO2024201248A1 (en) * 2023-03-24 2024-10-03 Pin Therapeutics, Inc. Compounds and methods for degrading gspt1
WO2025051180A1 (zh) * 2023-09-06 2025-03-13 上海超阳药业有限公司 内酰胺类衍生物及其应用
WO2025085416A1 (en) * 2023-10-16 2025-04-24 Bristol-Myers Squibb Company Gspt1 compounds and methods of use of the compounds
WO2025146112A1 (en) * 2024-01-05 2025-07-10 Primelink Biotherapeutics (Shenzhen) Co., Ltd. Gspt1 degrading compounds and compositions and uses thereof
WO2025179161A1 (en) 2024-02-21 2025-08-28 Innovo Therapeutics, Inc. Protein degrading compounds
WO2025259615A1 (en) * 2024-06-11 2025-12-18 Triana Biomedicines, Inc. Modulators of cdk2 and uses thereof
WO2026007898A1 (zh) * 2024-07-01 2026-01-08 上海海雁医药科技有限公司 含苯乙氧基亚烷基胺结构的异吲哚啉化合物、其药物组合物及应用

Family Cites Families (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20030045552A1 (en) * 2000-12-27 2003-03-06 Robarge Michael J. Isoindole-imide compounds, compositions, and uses thereof
BRPI0716092A2 (pt) * 2006-08-30 2013-09-17 Celgene Corp composto ou um sal, solvato, ou estereoisâmero do mesmo, composiÇço farmacÊutica, mÉtodo para tratar, controlar ou prevenir uma doenÇa ou distérbio, e, forma de dosagem de unidade simples.
CA2957226C (en) * 2008-10-29 2018-08-14 Celgene Corporation Isoindoline compounds for use in the treatment of cancer
TWI696615B (zh) * 2016-05-05 2020-06-21 瑞士商伊蘭科動物健康公司 雜芳基-1,2,4-三唑及雜芳基-三唑化合物
CN109790143A (zh) * 2016-05-10 2019-05-21 C4医药公司 用于靶蛋白降解的胺连接的c3-戊二酰亚胺降解决定子体
HUE070289T2 (hu) * 2016-10-11 2025-05-28 Arvinas Operations Inc Vegyületek és módszerek az androgénreceptor célzott lebontására
EP3743066A4 (en) * 2018-01-26 2021-09-08 Yale University IMIDE-BASED PROTEOLYSIS MODULATORS AND RELATED METHODS OF USE
CA3173118A1 (en) * 2020-03-31 2021-10-07 Orum Therapeutics, Inc. Neodegrader conjugates

Similar Documents

Publication Publication Date Title
JPWO2021069705A5 (enExample)
JP2021169499A5 (enExample)
JP2024050527A5 (enExample)
JP2020169171A5 (enExample)
JP2001526269A5 (enExample)
CN114430739A (zh) Egfr抑制剂、组合物及其制备方法
CA2679232A1 (en) Substituted 4-aryl-1,4-dihydro-1,6-naphthyridinamides and use thereof
JPWO2019213318A5 (enExample)
JP2006501181A5 (enExample)
JP2014015465A5 (enExample)
RU2013130250A (ru) Замещенные пуриновые и 7-деазапуриновые соединения
JP2005526857A5 (enExample)
JP2019500315A5 (enExample)
RU2010112450A (ru) Производные хиназолинона, полезные в качестве ванилоидных антагонистов
JP2021046404A5 (enExample)
JP2006507355A5 (enExample)
JP2005536519A5 (enExample)
JPWO2022152821A5 (enExample)
JP2019528279A5 (enExample)
JPWO2020023560A5 (enExample)
JPWO2019165358A5 (enExample)
RU92016234A (ru) Производные 3(2н)-пиридазинона, способ их получения, применение, фармацевтическая композиция, способ лечения
ATE24503T1 (de) Phenylpiperazin-derivate und verfahren zu deren herstellung.
JPWO2021003310A5 (enExample)
JP2019533007A5 (enExample)